Tags

Type your tag names separated by a space and hit enter

Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer.
Am J Clin Oncol. 2008 Dec; 31(6):585-8.AJ

Abstract

OBJECTIVES

The present study was conducted to investigate the sensitivity, specificity, predictive values and accuracy of serum CA125 and Bcl-2 levels and their combination in advanced epithelial ovarian cancer patients.

METHODS

Healthy controls (n = 117) with no gynecologic problems and patients with ovarian carcinoma (n = 117), pathologically verified, consecutively admitted to the Istanbul University, Oncology Institute during a one-year period were investigated. Serum Bcl-2 and CA125 were determined by using enzyme linked immunosorbent assay method.

RESULTS

The serum bcl-2 and CA125 levels were significantly higher in patients with ovarian cancer than in the control group (P < 0.001). The diagnostic sensitivity and specificity, predictive values and accuracies were calculated for each marker and their combination.

CONCLUSION

The best result was achieved with the combination of CA125-bcl-2. This combination fulfills the need of diagnosis of ovarian carcinoma for the best sensitivity and specificity.

Authors+Show Affiliations

Department of Preventive Oncology, Biostatistics and Epidemiology, Institute of Oncology, University of Istanbul, Istanbul, Turkey. hcamlica@istanbul.edu.trNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

19060592

Citation

Camlica, Hakan, et al. "Statistical Interpretation of CA125 and Bcl-2 in Serum of Patients With Late Stage Ovarian Cancer." American Journal of Clinical Oncology, vol. 31, no. 6, 2008, pp. 585-8.
Camlica H, Duranyildiz D, Tas F, et al. Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer. Am J Clin Oncol. 2008;31(6):585-8.
Camlica, H., Duranyildiz, D., Tas, F., & Yasasever, V. (2008). Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer. American Journal of Clinical Oncology, 31(6), 585-8. https://doi.org/10.1097/COC.0b013e318174dbd2
Camlica H, et al. Statistical Interpretation of CA125 and Bcl-2 in Serum of Patients With Late Stage Ovarian Cancer. Am J Clin Oncol. 2008;31(6):585-8. PubMed PMID: 19060592.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer. AU - Camlica,Hakan, AU - Duranyildiz,Derya, AU - Tas,Faruk, AU - Yasasever,Vildan, PY - 2008/12/9/pubmed PY - 2009/1/14/medline PY - 2008/12/9/entrez SP - 585 EP - 8 JF - American journal of clinical oncology JO - Am J Clin Oncol VL - 31 IS - 6 N2 - OBJECTIVES: The present study was conducted to investigate the sensitivity, specificity, predictive values and accuracy of serum CA125 and Bcl-2 levels and their combination in advanced epithelial ovarian cancer patients. METHODS: Healthy controls (n = 117) with no gynecologic problems and patients with ovarian carcinoma (n = 117), pathologically verified, consecutively admitted to the Istanbul University, Oncology Institute during a one-year period were investigated. Serum Bcl-2 and CA125 were determined by using enzyme linked immunosorbent assay method. RESULTS: The serum bcl-2 and CA125 levels were significantly higher in patients with ovarian cancer than in the control group (P < 0.001). The diagnostic sensitivity and specificity, predictive values and accuracies were calculated for each marker and their combination. CONCLUSION: The best result was achieved with the combination of CA125-bcl-2. This combination fulfills the need of diagnosis of ovarian carcinoma for the best sensitivity and specificity. SN - 1537-453X UR - https://www.unboundmedicine.com/medline/citation/19060592/Statistical_interpretation_of_CA125_and_Bcl_2_in_serum_of_patients_with_late_stage_ovarian_cancer_ L2 - https://doi.org/10.1097/COC.0b013e318174dbd2 DB - PRIME DP - Unbound Medicine ER -